StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)

Research analysts at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a note issued to investors on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Shares of EVOK stock opened at $4.26 on Tuesday. Evoke Pharma has a 1-year low of $3.54 and a 1-year high of $17.88. The stock’s fifty day moving average price is $5.08 and its 200 day moving average price is $5.52. The company has a market cap of $3.49 million, a price-to-earnings ratio of -0.41 and a beta of 0.36.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%. The firm had revenue of $2.55 million for the quarter.

Institutional Trading of Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.